Press Release & Publications

2023-11-09

鼓舞人心的AG-73305臨床 2a試驗數據顯示了初步安全性和有效性

DME患者中在單次玻璃體內注射0.5、1、2和4 mg劑量後，發現AG-7330 […]
Do you like it?
Read more
2023-11-09

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology

ALHAMBRA, Calif., Nov. 8, 2023  […]
Do you like it?
Read more
2023-09-30

Allgenesis to Present Initial Data from Phase 2a Study of AG-73305, a Novel Bispecific Anti-VEGF and Anti-Integrin Fc-Fusion Protein for the Treatment of DME at AAO 2023

September 30th, 2023 Alhambra, Californi […]
Do you like it?
Read more
2023-06-19

Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients

Taipei, Taiwan June. 19th, 2023 Allgenes […]
Do you like it?
Read more
2023-05-29

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema

Taipei, Taiwan May 24th, 2023 · AG-73305 […]
Do you like it?
Read more
2023-04-18

Allgenesis Announces Last Patient Enrolled in the Phase 2a Trial Evaluating the Safety and Efficacy of AG-73305 in Diabetic Macular Edema (DME) Patients

Taipei, Taiwan/April 18, 2023 Allgenesis […]
Do you like it?
Read more
Load more